Express Scripts Holding Profit Margins 2006-2018 | ESRX

Current and historical gross, operating and net profit margins for Express Scripts Holding (ESRX) over the last 10 years. The current net profit margin for Express Scripts Holding (ESRX) as of March 31, 2018 is 4.59%.
Sector Industry Market Cap Revenue
Medical Medical Services $0.008B $100.065B
Express Scripts Holding Company puts medicine within reach of tens of millions of people by aligning with plan sponsors, taking bold action and delivering patient-centered care to make better health more affordable and accessible. Headquartered in St. Louis, Express Scripts provides integrated pharmacy benefit management services, including network-pharmacy claims processing, home delivery pharmacy care, specialty pharmacy care, specialty benefit management, benefit-design consultation, drug utilization review, formulary management, and medical and drug data analysis services. Express Scripts also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services.
Stock Name Country Market Cap PE Ratio
ICON (ICLR) Ireland $7.482B 25.11
PRA Health Sciences (PRAH) United States $6.485B 31.04
Charles River Laboratories (CRL) United States $5.851B 22.74
HealthEquity (HQY) United States $5.087B 107.87
Premier (PINC) United States $4.963B 20.08
INC Research Holdings (SYNH) United States $4.959B 21.83
Teladoc (TDOC) United States $4.388B 0.00
NovoCure (NVCR) Jersey $3.383B 0.00
AMN Healthcare Services Inc (AMN) United States $2.943B 22.44
Intrexon (XON) United States $1.897B 0.00
Medpace Holdings (MEDP) United States $1.673B 26.61
BioTelemetry (BEAT) United States $1.650B 45.73
IKang Healthcare (KANG) China $1.428B 79.08
Healthways (TVTY) United States $1.368B 19.38
Natera (NTRA) United States $1.289B 0.00
China Cord Blood (CO) China $0.995B 26.61
Apollo Medical Holdings (AMEH) United States $0.908B 0.00
Surgery Partners (SGRY) United States $0.680B 0.00
Civitas Solutions (CIVI) United States $0.603B 15.37
CareDx (CDNA) United States $0.441B 0.00
OncoCyte (OCX) United States $0.126B 0.00
Interpace Diagnostics (IDXG) United States $0.029B 0.00
Cancer Genetics (CGIX) United States $0.026B 0.00
Biocept (BIOC) United States $0.015B 0.00
OpGen (OPGN) United States $0.012B 0.00
FORM Holdings (XSPA) United States $0.008B 0.00